| Chronic Lymphocytic Leukemia
Jaypirca vs Rituxan Hycela
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Jaypirca vs Rituxan Hycela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRituxan Hycela has a higher rate of injection site reactions vs Jaypirca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rituxan Hycela but not Jaypirca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jaypirca
Rituxan Hycela
At A Glance
Oral
Once daily
BTK inhibitor
SC injection
Every 3-4 weeks
CD20-directed antibody
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
Dosing
Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Lymphoma, Follicular 1,400 mg/23,400 Units SC; for relapsed/refractory FL, once weekly for 3 or 7 weeks following an initial IV rituximab dose (4 or 8 weeks total); for previously untreated FL, on Day 1 of Cycles 2-8 of chemotherapy every 21 days, then maintenance every 8 weeks for 12 doses; for non-progressing FL after CVP, once weekly for 3 weeks every 6 months to a maximum of 16 doses.
Diffuse Large B-Cell Lymphoma 1,400 mg/23,400 Units SC on Day 1 of Cycles 2-8 of CHOP chemotherapy every 21 days for up to 7 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (up to 6-8 cycles total).
Chronic Lymphocytic Leukemia 1,600 mg/26,800 Units SC on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide every 28 days for 5 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (6 cycles total).
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased
Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion
Most common (>=20%) Infections, neutropenia, nausea, constipation, cough, fatigue (FL); infections, neutropenia, alopecia, nausea, anemia (DLBCL); infections, neutropenia, nausea, thrombocytopenia, pyrexia, vomiting, injection site erythema (CLL).
Serious Mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy, hypersensitivity and administration reactions, tumor lysis syndrome, infections, cardiac arrhythmias, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, fatal cardiac failure, uveitis, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease.
Pharmacology
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.
Anti-CD20 chimeric murine/human IgG1 monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC); combined with hyaluronidase human, which transiently depolymerizes subcutaneous hyaluronan to enhance rituximab absorption into systemic circulation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jaypirca
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Rituxan Hycela
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Jaypirca
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (1/8) · Qty limit (2/8)
Rituxan Hycela
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jaypirca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Rituxan Hycela
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rituxan Hycela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JaypircaView full Jaypirca profile
Rituxan HycelaView full Rituxan Hycela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.